We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$27.5B
$4.43M 0.43%
+37,000
New +$4.42M
RLYP
52
DELISTED
RELYPSA INC COM
RLYP
$4.37M 0.43%
132,000
-3,000
-2% -$103K
ZVRA icon
53
Zevra Therapeutics
ZVRA
$562M
$4.36M 0.43%
+14,844
New +$3.24M
ICPT
54
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.22M 0.41%
17,500
+2,500
+17% +$666K
GNCA
55
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.15M 0.41%
37,775
+22,250
+143% +$2.07M
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.09M 0.4%
128,000
-22,000
-15% -$558K
BITI
57
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$3.93M 0.39%
+196,800
New +$4.11M
FEZ icon
58
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.42B
$3.93M 0.38%
104,920
+10,920
+12% +$431K
PTLA
59
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.92M 0.38%
86,000
-14,023
-14% -$564K
MDVN
60
DELISTED
MEDIVATION, INC.
MDVN
$3.9M 0.38%
68,230
-4,000
-6% -$247K
FOMX
61
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.9M 0.38%
380,000
+180,000
+90% +$1.99M
ASRT
62
DELISTED
Assertio
ASRT
$3.86M 0.38%
3,000
-333
-10% -$456K
ALPN
63
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.86M 0.38%
+63,750
New +$3.8M
RCPT
64
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$3.8M 0.37%
20,000
+2,500
+14% +$413K
VIRX
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.72M 0.36%
5,881
-309
-5% -$164K
ATYR
66
aTyr Pharma
ATYR
$47.6M
$3.7M 0.36%
+14,931
New +$4.64M
AOS icon
67
A.O. Smith
AOS
$8.17B
$3.64M 0.36%
101,240
-21,960
-18% -$757K
KRE icon
68
State Street SPDR S&P Regional Banking ETF
KRE
$4.5B
$3.54M 0.35%
+80,080
New +$3.4M
DVAX
69
DELISTED
Dynavax Technologies
DVAX
$3.51M 0.34%
+150,000
New +$3.27M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$3.5M 0.34%
48,000
-17,724
-27% -$1.14M
KITE
71
DELISTED
Kite Pharma, Inc.
KITE
$3.47M 0.34%
56,970
-9,000
-14% -$513K
MRNS
72
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.46M 0.34%
74,633
+21,250
+40% +$794K
ARWR icon
73
Arrowhead Research
ARWR
$11.9B
$3.4M 0.33%
+475,000
New +$3.26M
HALO icon
74
Halozyme
HALO
$9.79B
$3.39M 0.33%
+150,000
New +$2.64M
OCUL icon
75
Ocular Therapeutix
OCUL
$1.79B
$3.37M 0.33%
+160,000
New +$3.96M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.